Novartis' asthma drug fails in phase 3, raising doubts about Gossamer's prospects

[cafead]

via Novartis’ asthma prospect fevipiprant has failed to improve lung function in two phase 3 trials. The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

article source

 

[Woody]

Not good for No-fart-us!